



Clinical Presentations on Synchrony® IOL Receive Top Honors at Annual Meeting of American Academy of Ophthalmology
Patient Outcomes Suggest Physiologic Design and Unique Mechanism of Action Providing True Accommodation

IRVINE, CA, November 18, 2008-- The Synchrony® dual optic accommodating intraocular lens (IOL) from Visiogen, Inc. was well received at the annual meeting of the American Academy of Ophthalmology (AAO) recently held in Atlanta, Georgia.

Clinical data from randomized controlled trials on the Synchrony lens were featured in four platform presentations and three posters. All three of the posters were among the ten awarded the ‘Best of’ designation at the meeting.

The three picks for ‘Best of’ included posters “Reading Speed with Synchrony Dual Optic Accommodating IOL”, “Comparative Study of Reading Performance under Different Lighting Conditions between Accommodating and Multifocal IOLs” and “Long-term Functional Performance after Synchrony Dual Optic Accommodating IOL Implantation.”

Platform presentations included, “Which Premium IOLs Should I Use: Accommodating or Multifocal?”, “Innovations in Accommodating IOLs”, “Functional Vision in

Presbyopia-Correcting IOLs: Randomized Double-Masked Clinical Trial Comparing Synchrony and ReSTOR” and “Update on Synchrony Dual Optic Accommodating IOL.”

“The three top posters received the highest grades within their subject area based on review by the Annual Meeting Program Committee,” said Reza Zadno, President and CEO of Visiogen, Inc. “Visiogen is proud to be raising the standard for objective clinical science by supporting multiple randomized, controlled clinical trials on the Synchrony lens. The results of these award-winning studies are yet more evidence that Synchrony’s unique three-dimensional design and physiologic mechanism of action make it the first truly accommodating lens design.”

About Visiogen

Visiogen, Inc. is focused on developing innovative products for cataract and refractive patients. Founded in Irvine, California, in 2001, Visiogen’s first commercial application, Synchrony®, a 3-dimensional dual optic accommodating intraocular lens and pre-loaded injector, is currently in the final phase of a U.S. IDE study, and has received the CE Mark in Europe. More information about Visiogen and the Synchrony technology can be found at www.visiogen.com.

More information on the company and its offerings can also be obtained by contacting:

Kate Jennings
Maricich Brand Communications for Visiogen, Inc.
Tel. 949-223-6455
Fax 949-223-6451
kate@maricich.com

Kevin Hykes
Chief Commercial Officer
Visiogen, Inc.
info@visiogen.com